15,100 Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART) Purchased by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS purchased a new stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 15,100 shares of the life sciences company’s stock, valued at approximately $342,000.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Intech Investment Management LLC raised its holdings in shares of Integra LifeSciences by 86.4% during the fourth quarter. Intech Investment Management LLC now owns 24,113 shares of the life sciences company’s stock valued at $547,000 after acquiring an additional 11,174 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Integra LifeSciences by 70.4% in the 4th quarter. Thrivent Financial for Lutherans now owns 93,427 shares of the life sciences company’s stock worth $2,119,000 after purchasing an additional 38,597 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Integra LifeSciences by 33.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 19,755 shares of the life sciences company’s stock valued at $448,000 after purchasing an additional 4,967 shares in the last quarter. Inceptionr LLC purchased a new position in shares of Integra LifeSciences during the fourth quarter valued at about $351,000. Finally, Raymond James Financial Inc. bought a new position in Integra LifeSciences in the fourth quarter worth about $943,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

Shares of NASDAQ IART opened at $19.57 on Friday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The company has a 50 day simple moving average of $23.37 and a two-hundred day simple moving average of $22.30. Integra LifeSciences Holdings Co. has a fifty-two week low of $16.81 and a fifty-two week high of $34.79. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -217.42, a P/E/G ratio of 0.73 and a beta of 1.24.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. During the same quarter last year, the company earned $0.89 EPS. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. Analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, Integra LifeSciences presently has an average rating of “Hold” and an average target price of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.